Life Science Nation

A venture capital firm based in Western Europe is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses on Seed investments in the form of equity. Typical allocation is up to $5M for the first ticket. Forty51 Ventures invests in European companies but is open to global opportunities....

Hot Investor Mandate: VC Firm With Inaugural Fund Seeks Therapeutics Companies in Oncology, CNS, Rare Diseases, and More With a Focus in Western Europe A venture capital firm based in Western Europe is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses o…

A Venture Capital firm based in the US typically invests between $3-5M initially and $6M to $10M over the lifetime of the investment. Investments are generally in the form of milestone based equity tranches, however the firm also has experience in working with convertible notes. The firm is currently looking for early stage companies in the Therapeutics, Diagnostics, Medical Device and Healthcare IT spaces....

Hot Investor Mandate: USA-Based VC Invests Up to $10M Over Company’s Lifecycle in Life Science Companies, Preferring Early Clinical Stage Opportunities A Venture Capital firm based in the US typically invests between $3-5M initially and $6M to $10M over the lifetime of the investment. Investments are generally in the form of milestone based equity…

A venture capital firm in the US is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm currently has >$200M AUM and is investing from their second fund. The firm is looking to engage in Seed to Series A financing rounds with initial check sizes between $4-8M. The firm will also make sub $1M investments in some cases, and will consider convertible notes for these checks....

Hot Investor Mandate: Investment Firm Focuses on Investing in Medical Devices, Diagnostics, and Digital Health Companies from Seed to Series A Across the Globe A venture capital firm in the US is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm currently has >$200M AUM and is investing fro…

A USA-based growth equity fund is investing out of its latest fund which closed last year. The firm makes equity investments in commercial stage (post regulatory approval) healthcare companies with meaningful revenue and traction. The firm typically invests between $20-60m per company, and focuses on companies in USA and Canada. The firm invests exclusively in healthcare and is open to all sub-sectors within the industry including products and services....

Hot Investor Mandate: Growth Equity Fund Invests $20-60M in Revenue Generating Healthcare Companies in North America A USA-based growth equity fund is investing out of its latest fund which closed last year. The firm makes equity investments in commercial stage (post regulatory approval) healthcare companies with…

A hybrid family office can make investments ranging from $500k-100M into companies, and due to its funding structure, has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes opportunistic and strategic investments, and does not have a target minimum or maximum number of investments for any given year....

Hot Investor Mandate: USA-Based Family Office Invests Across All Life Science Sectors, Most Interested in Clinical Stage Companies, Capable of Investing Up to $100M A hybrid family office can make investments ranging from $500k-100M into companies, and due to its funding structure, has no requirements for holding period or capital structure. The firm makes inv…

A healthcare and life sciences focused venture capital firm with USA and China offices has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD....

Hot Investor Mandate: Investment Firm Allocates Up to $15M in Global Life Science Opportunities, With a Focus on US and China-Based Opportunities A healthcare and life sciences focused venture capital firm with USA and China offices has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over …

A venture capital firm with offices in the UK and USA is actively seeking innovative investment opportunities with high potential for growth. With its current fund, the firm invests in digital technologies in the life sciences space. The firm prefers to invest in venture to growth stage companies – in general, companies looking for seed funding will be considered too early-stage for the firm....

Hot Investor Mandate: VC Firm With UK and USA Offices Seeks Life Science Technologies With Digital Component, Investing Up to $10M A venture capital firm with offices in the UK and USA is actively seeking innovative investment opportunities with high potential for growth. With its current fund, the firm invests in digital tech…

A venture capital firm based in the US is currently allocating capital from its third fund, investing between $1-2M in pre-seed and seed-stage companies, targeting approximately 10% as their ownership target. The fund is ~75% deployed and expects to make several more investments over the upcoming quarters. The firm will consider opportunities in the United States and Canada. Within healthcare and life science, the firm is interested in AI-based, non-consumer healthcare IT products....

Hot Investor Mandate: USA-Based VC Invests in Seed-Stage Healthcare IT and AI-Based Life Sciences Companies, Prefers to Lead Rounds A venture capital firm based in the US is currently allocating capital from its third fund, investing between $1-2M in pre-seed and seed-stage companies, targeting approximately 10% as their owners…

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN Why should tech hubs attend partnering conferences like the Redefining Early Stage Investments (RESI)? Attending RESI provides a unique and valuable platform for incubators, accelerators, universities, non-profits, and government organizations to engage with early-stage life science startups, service providers and investors. It enables attendees like tech hubs to discover new opportunities, build relationships, gain insights, and enhance their overall impact within the startup ecosystem....

RESI Partnering is Open – All Tech Hub Affiliates Get Discounted Rates By Erika Wu, Business Development Manager, Global Tech Hubs, LSN Why should tech hubs attend partnering conferences like the Redefining Early Stage Investments (RESI)? Attending RESI provides a uni…

A life science venture capital firm with strong China expertise and global capabilities discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in US and China. The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services....

Hot Investor Mandate: Life Science VC with Strong China Market Expertise Seeks Novel Therapeutics Across All Modalities from Seed to Growth Stage A life science venture capital firm with strong China expertise and global capabilities discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. T…

A venture capital firm in the US invests in cancer-focused data accessibility and scalability, infrastructure, education and access, and IT and service start-ups as they look to fundamentally change the way cancer care is designed and delivered at scale. Drugs, therapeutics, or medical devices are not of interest. The firm will invest in Seed stage companies that are currently selling in the market....

Hot Investor Mandate: USA-Based VC Invests in Cancer-Focused Digital Health Technologies, Typically Investing in Seed Opportunities A venture capital firm in the US invests in cancer-focused data accessibility and scalability, infrastructure, education and access, and IT and service start-ups as they look to fundamentally chang…

A leading European venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing therapeutic treatments to patients, with a focus on indications with high unmet needs. The firm has a diverse international team in Spain that is driven by science, with the ambition to transform capital into medical breakthroughs. The firm has over €400M million in assets under management through its three funds....

Hot Investor Mandate: European Investment Firm Seeks Innovative Therapeutics Opportunities, Investing Up to €20M Over the Company’s Lifecycle A leading European venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing therapeutic treatments to pat…